BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16908838)

  • 1. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
    Fulci G; Breymann L; Gianni D; Kurozomi K; Rhee SS; Yu J; Kaur B; Louis DN; Weissleder R; Caligiuri MA; Chiocca EA
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12873-8. PubMed ID: 16908838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis.
    Wakimoto H; Fulci G; Tyminski E; Chiocca EA
    Gene Ther; 2004 Jan; 11(2):214-23. PubMed ID: 14712306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
    Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
    J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
    Friedman A; Tian JP; Fulci G; Chiocca EA; Wang J
    Cancer Res; 2006 Feb; 66(4):2314-9. PubMed ID: 16489036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
    Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
    Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.
    Fulci G; Dmitrieva N; Gianni D; Fontana EJ; Pan X; Lu Y; Kaufman CS; Kaur B; Lawler SE; Lee RJ; Marsh CB; Brat DJ; van Rooijen N; Stemmer-Rachamimov AO; Hochberg FH; Weissleder R; Martuza RL; Chiocca EA
    Cancer Res; 2007 Oct; 67(19):9398-406. PubMed ID: 17909049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.
    Kurozumi K; Hardcastle J; Thakur R; Yang M; Christoforidis G; Fulci G; Hochberg FH; Weissleder R; Carson W; Chiocca EA; Kaur B
    J Natl Cancer Inst; 2007 Dec; 99(23):1768-81. PubMed ID: 18042934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.
    Zemp FJ; McKenzie BA; Lun X; Reilly KM; McFadden G; Yong VW; Forsyth PA
    Cancer Res; 2014 Dec; 74(24):7260-73. PubMed ID: 25336188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.
    Ikeda K; Ichikawa T; Wakimoto H; Silver JS; Deisboeck TS; Finkelstein D; Harsh GR; Louis DN; Bartus RT; Hochberg FH; Chiocca EA
    Nat Med; 1999 Aug; 5(8):881-7. PubMed ID: 10426310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
    Kambara H; Saeki Y; Chiocca EA
    Cancer Res; 2005 Dec; 65(24):11255-8. PubMed ID: 16357128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
    Hellums EK; Markert JM; Parker JN; He B; Perbal B; Roizman B; Whitley RJ; Langford CP; Bharara S; Gillespie GY
    Neuro Oncol; 2005 Jul; 7(3):213-24. PubMed ID: 16053696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
    Nakashima H; Kaufmann JK; Wang PY; Nguyen T; Speranza MC; Kasai K; Okemoto K; Otsuki A; Nakano I; Fernandez S; Goins WF; Grandi P; Glorioso JC; Lawler S; Cripe TP; Chiocca EA
    J Clin Invest; 2015 Nov; 125(11):4269-80. PubMed ID: 26524593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.
    Han J; Chen X; Chu J; Xu B; Meisen WH; Chen L; Zhang L; Zhang J; He X; Wang QE; Chiocca EA; Kaur B; Caligiuri MA; Yu J
    Cancer Res; 2015 Dec; 75(24):5273-82. PubMed ID: 26631269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
    Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
    Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varicella zoster virus infection of malignant glioma cell cultures: a new candidate for oncolytic virotherapy?
    Leske H; Haase R; Restle F; Schichor C; Albrecht V; Vizoso Pinto MG; Tonn JC; Baiker A; Thon N
    Anticancer Res; 2012 Apr; 32(4):1137-44. PubMed ID: 22493342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.
    Määttä AM; Liimatainen T; Wahlfors T; Wirth T; Vähä-Koskela M; Jansson L; Valonen P; Häkkinen K; Rautsi O; Pellinen R; Mäkinen K; Hakumäki J; Hinkkanen A; Wahlfors J
    Int J Cancer; 2007 Aug; 121(4):863-70. PubMed ID: 17443493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
    Wakimoto H; Johnson PR; Knipe DM; Chiocca EA
    Gene Ther; 2003 Jun; 10(11):983-90. PubMed ID: 12756419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
    Wu J; Jordan M; Waxman DJ
    BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.